Microbiome-Derived Effectors Converge on Host Pathways to Drive Organ Injury and Fibrosis
Background
The gut microbiome acts as a complex endocrine-like network, producing diverse metabolites, ligands, and peptides crucial for host physiology. While maintaining epithelial integrity, immune homeostasis, and metabolic regulation under normal conditions, dysbiosis alters the systemic distribution of these effectors, promoting injury. A critical gap exists in understanding how this chemical diversity translates into convergent host responses, particularly in chronic conditions like pulmonary fibrosis, chronic kidney disease, and hepatobiliary inflammation, where current treatments often fall short.
Study Design
This review synthesizes current understanding of how microbiome-derived effectors influence host physiology and pathology. It systematically examines the chemical diversity of these signals and their convergent impact on host pathways implicated in organ injury and fibrosis. The authors integrated findings from various studies to establish a comprehensive framework linking gut dysbiosis to systemic disorders, highlighting the emerging role of microbial peptides as a distinct layer of regulation.
Results
The review establishes that despite their chemical diversity, microbiome-derived signals consistently converge on a limited set of host pathways. These critical pathways include pattern-recognition receptor activation, mitochondrial dysfunction, apoptosis and senescence, inflammatory amplification, and fibrosis. This convergence collectively determines tissue vulnerability across organ systems, linking gut imbalance to conditions like pulmonary fibrosis, acute lung injury, chronic kidney disease, and hepatobiliary inflammation. Microbial peptides, such as corisin, are identified as an emerging regulatory layer, directly engaging intracellular targets and amplifying tissue injury. The proposed framework redefines microbiome-associated disease as a disorder of microbial chemistry and host pathway activation, providing a foundation for future research.
This framework links gut imbalance to disorders such as pulmonary fibrosis, acute lung injury, chronic kidney disease, and hepatobiliary inflammation.
Key Findings
- Microbiome-derived effectors function as an endocrine-like network, shaping host physiology.
- Dysbiosis alters these effectors, shifting host responses towards organ injury and fibrosis.
- Diverse microbiome signals converge on a limited set of host pathways (e.g.,
mitochondrial dysfunction,fibrosis). - Microbial peptides represent an emerging regulatory layer, directly engaging intracellular targets.
- The framework links gut imbalance to systemic disorders like pulmonary fibrosis and chronic kidney disease.
Why It Matters
This comprehensive framework fundamentally shifts how we understand microbiome-associated diseases, moving beyond simple dysbiosis to a focus on specific microbial chemistry and host pathway activation. For clinicians and researchers, this means identifying mechanism-based biomarkers for early detection and risk stratification, and developing targeted therapeutic strategies that precisely modulate these convergent pathways or microbial effectors. It suggests that interventions could focus on specific microbial peptides or their host targets, rather than broad-spectrum microbiome alterations, paving the way for more precise and effective treatments for conditions like pulmonary fibrosis or chronic kidney disease. This reframing offers a clearer path towards translational applications.
microbiome
dysbiosis
organ-injury
fibrosis
microbial-peptides
inflammation